Methods of Treating Ovarian Cancer

Abstract

The present invention provides methods of administering a PARP inhibitor to a cancer patient.

1 .- 90 . (canceled) 
     
     
         91 . A method of treating a patient diagnosed with cancer and at risk for thrombocytopenia, the method comprising administering to said patient a dose of niraparib tosylate monohydrate equivalent to about 200 mg or about 300 mg of niraparib free base, wherein the patient is HRD negative and wherein the patient has shown a partial or complete response to platinum-based chemotherapy;
 wherein the dose of niraparib tosylate monohydrate equivalent to about 300 mg of niraparib free base is reduced to a dose equivalent to about 200 mg of niraparib free base if the patient exhibits thrombocytopenia; and   wherein the dose of niraparib tosylate monohydrate equivalent to about 200 mg of niraparib free base is reduced to a dose equivalent to about 100 mg of niraparib free base if the patient exhibits thrombocytopenia.   
     
     
         92 . The method of  claim 91 , wherein the niraparib tosylate monohydrate is administered in a single daily dose. 
     
     
         93 . The method of  claim 91 , wherein the niraparib tosylate monohydrate is administered orally. 
     
     
         94 . The method of  claim 93 , wherein the niraparib tosylate monohydrate is administered in the form of one or more unit dosage forms equivalent to about 100 mg of niraparib free base. 
     
     
         95 . The method of  claim 94 , wherein the one or more unit dosage forms are capsules. 
     
     
         96 . The method of  claim 91 , wherein the administration of niraparib tosylate monohydrate is commenced within 8 weeks of the end of the last cycle of platinum-based chemotherapy. 
     
     
         97 . The method of  claim 91 , wherein the patient is diagnosed with advanced or recurrent epithelial ovarian cancer. 
     
     
         98 . The method of  claim 91 , wherein the patient is diagnosed with advanced or recurrent fallopian tube cancer. 
     
     
         99 . The method of  claim 91 , wherein the patient is diagnosed with advanced or recurrent primary peritoneal cancer. 
     
     
         100 . The method of  claim 91 , wherein the treatment is maintenance treatment. 
     
     
         101 . The method of  claim 91 , wherein the patient is an adult. 
     
     
         102 . A method of treating a patient diagnosed with cancer and at risk for thrombocytopenia, the method consisting of administering to said patient a dose of niraparib tosylate monohydrate equivalent to about 200 mg or about 300 mg of niraparib free base, wherein the patient is HRD negative and wherein the patient has shown a partial or complete response to platinum-based chemotherapy;
 wherein the dose of niraparib tosylate monohydrate equivalent to about 300 mg of niraparib free base is reduced to a dose equivalent to about 200 mg of niraparib free base if the patient exhibits thrombocytopenia; and   wherein the dose of niraparib tosylate monohydrate equivalent to about 200 mg of niraparib free base is reduced to a dose equivalent to about 100 mg of niraparib free base if the patient exhibits thrombocytopenia.   
     
     
         103 . The method of  claim 102 , wherein the niraparib tosylate monohydrate is administered in a single daily dose. 
     
     
         104 . The method of  claim 102 , wherein the niraparib tosylate monohydrate is administered orally. 
     
     
         105 . The method of  claim 102 , wherein the administration of niraparib tosylate monohydrate is commenced within 8 weeks of the end of the last cycle of platinum-based chemotherapy. 
     
     
         106 . The method of  claim 102 , wherein the patient is diagnosed with advanced or recurrent epithelial ovarian cancer. 
     
     
         107 . The method of  claim 102 , wherein the patient is diagnosed with advanced or recurrent fallopian tube cancer. 
     
     
         108 . The method of  claim 102 , wherein the patient is diagnosed with advanced or recurrent primary peritoneal cancer. 
     
     
         109 . A method of treating a patient diagnosed with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and at risk for thrombocytopenia, the method comprising administering daily to said patient an oral dose of niraparib tosylate monohydrate equivalent to about 200 mg or about 300 mg of niraparib free base, wherein the patient is HRD negative and wherein the patient has shown a partial or complete response to platinum-based chemotherapy;
 wherein the daily oral dose of niraparib tosylate monohydrate equivalent to about 300 mg of niraparib free base is reduced to a dose equivalent to about 200 mg of niraparib free base if the patient exhibits thrombocytopenia; and   wherein the daily oral dose of niraparib tosylate monohydrate equivalent to about 200 mg of niraparib free base is reduced to a dose equivalent to about 100 mg of niraparib free base if the patient exhibits thrombocytopenia.   
     
     
         110 . The method of  claim 109 , wherein the administration of niraparib tosylate monohydrate is commenced within 8 weeks of the end of the last cycle of platinum-based chemotherapy. 
     
     
         111 . The method of  claim 109 , wherein the patient is diagnosed with advanced or recurrent epithelial ovarian cancer. 
     
     
         112 . The method of  claim 109 , wherein the patient is diagnosed with advanced or recurrent fallopian tube cancer. 
     
     
         113 . The method of  claim 109 , wherein the patient is diagnosed with advanced or recurrent primary peritoneal cancer. 
     
     
         114 . A method of treating a patient diagnosed with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and at risk for thrombocytopenia, the method consisting of administering daily to said patient an oral dose of niraparib tosylate monohydrate equivalent to about 200 mg or about 300 mg of niraparib free base, wherein the patient is HRD negative and wherein the patient has shown a partial or complete response to platinum-based chemotherapy;
 wherein the daily oral dose of niraparib tosylate monohydrate equivalent to about 300 mg of niraparib free base is reduced to a dose equivalent to about 200 mg of niraparib free base if the patient exhibits thrombocytopenia; and   wherein the daily oral dose of niraparib tosylate monohydrate equivalent to about 200 mg of niraparib free base is reduced to a dose equivalent to about 100 mg of niraparib free base if the patient exhibits thrombocytopenia.   
     
     
         115 . The method of  claim 114 , wherein the administration of niraparib tosylate monohydrate is commenced within 8 weeks of the end of the last cycle of platinum-based chemotherapy. 
     
     
         116 . The method of  claim 114 , wherein the patient is diagnosed with advanced or recurrent epithelial ovarian cancer. 
     
     
         117 . The method of  claim 114 , wherein the patient is diagnosed with advanced or recurrent fallopian tube cancer. 
     
     
         118 . The method of  claim 114 , wherein the patient is diagnosed with advanced or recurrent primary peritoneal cancer.